In a groundbreaking achievement, Magdalena Biosciences, a joint venture between Filament Health Corp. and Jaguar Health, has successfully completed the importation of coca leaf from Peru. This remarkable feat was made possible through the partnership with Empresa Nacional de la Coca (ENACO), the sole authorized company in Peru responsible for the collection, distribution, and exportation of coca leaf and its derivatives. The importation process received the official approval of the Peruvian Health Authority, Dirección General de Medicamentos Insumos y Drogas (DIGEMID), further solidifying its significance.
Psilo Scientific, a wholly-owned subsidiary of Filament Health, took delivery of the imported coca leaves at their state-of-the-art research and development facility located in Metro Vancouver. These precious leaves will play a pivotal role in the initial stages of research, specifically focusing on exploring neuropsychiatric indications. Filament Health, a visionary clinical-stage natural psychedelic drug development company, firmly believes in the immense potential of safe, standardized, naturally-derived psychedelic medicines. Conversely, Jaguar Health is dedicated to the pursuit of discovering and developing natural medicines derived from psychedelic and psychoactive plants, aiming to unlock their therapeutic benefits.
This milestone not only showcases the determination and expertise of Magdalena Biosciences but also highlights the immense possibilities that lie within the realm of psychedelic medicine. With their shared commitment to advancing the field of natural medicine, Filament Health Corp. and Jaguar Health are poised to revolutionize the way we approach healthcare, offering hope and healing through innovative and responsible means.